NPI: 1538316617 · ORLANDO, FL 32808 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 08/20/2008
Authorized official WINSTEL, JOHN controls 20+ related entities in our dataset. Read more
| Authorized Official | WINSTEL, JOHN (CHIEF ACCOUNTING OFFICER) |
| NPI Enumeration Date | 08/20/2008 |
Other providers sharing the same authorized official: WINSTEL, JOHN
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 21,899 | $3.78M |
| 2019 | 25,283 | $3.63M |
| 2020 | 11,055 | $1.72M |
| 2021 | 9,103 | $968K |
| 2022 | 1,159 | $267K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 22,883 | 1,088 | $3.78M |
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 18,837 | 1,427 | $2.74M |
| J1270 | Injection, doxercalciferol, 1 mcg | 12,807 | 928 | $1.62M |
| A4657 | Syringe, with or without needle, each | 3,182 | 1,221 | $853K |
| J1756 | Injection, iron sucrose, 1 mg | 4,750 | 850 | $591K |
| 85041 | 1,054 | 661 | $144K | |
| 85048 | 1,051 | 658 | $144K | |
| 83540 | 963 | 645 | $119K | |
| 83550 | 963 | 645 | $118K | |
| 83970 | 858 | 566 | $111K | |
| 82728 | 613 | 423 | $74K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 242 | 118 | $40K |
| 82108 | 48 | 35 | $9K | |
| 82607 | 66 | 54 | $9K | |
| 82947 | 84 | 71 | $7K | |
| 90674 | 17 | 14 | $3K | |
| G0008 | Administration of influenza virus vaccine | 17 | 14 | $3K |
| 86706 | 24 | 23 | $0.00 | |
| 87340 | 16 | 15 | $0.00 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 24 | 23 | $0.00 |